10x Genomics has entered a partnership with PharosAI, a consortium of four leading UK institutions, to use its Xenium spatial platform to generate one of the world’s largest multimodal cancer datasets. The collaboration will combine genomic, transcriptomic, imaging and spatial biology data from archived NHS cancer samples and pair them with advanced AI models and analytical tools. The initiative is backed by £18.9 million from the UK Government’s Research Ventures Catalyst, with additional support from charities and industry partners, bringing total investment to more than £44 million.
The dataset will comprise thousands of archival tissue samples, initially focused on breast cancer and later expanding to lung and pancreatic cancers. By providing a rich, AI‑ready resource, 10x aims to accelerate earlier diagnosis, enable precision therapies and speed the discovery of new treatments. The partnership also positions 10x to deepen its footprint in the NHS research ecosystem and create new revenue channels through dataset licensing and AI‑driven analytics.
For 10x Genomics, the collaboration represents a strategic shift beyond its existing commercial customer base. The company’s Q3 2025 revenue was $149 million, a 2% decline from the same period in 2024, and it posted a net loss of $27.5 million. 10x is scheduled to report its Q4 2025 and full‑year 2025 results on February 12 2026. The PharosAI partnership signals management’s confidence in the company’s spatial biology platform and its potential to generate new, high‑margin data‑science services.
Professor Anita Grigoriadis, CEO of PharosAI and Professor of Molecular and Digital Pathology at King’s College London, said: “AI has the potential to transform cancer care, but its progress has been held back by fragmented and inaccessible data. PharosAI changes that – creating rich, multimodal datasets and pairing them with cutting‑edge AI models and analytical tools, powered by 10x Genomics’ advanced spatial technologies to enable earlier diagnoses, more targeted therapies and better outcomes for patients.”
The partnership underscores the growing importance of AI in life sciences and the UK’s commitment to advancing AI and life‑sciences research through significant public investment. By leveraging archived NHS samples, the initiative also taps into a vast reservoir of healthcare data, positioning 10x Genomics at the forefront of AI‑driven cancer research.
revised_sentiment_rating
}
importance
high
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.